TY - JOUR
T1 - CD8+ T-cell differentiation and dysfunction inform treatment response in acute myeloid leukemia
AU - Mazziotta, Francesco
AU - Biavati, Luca
AU - Rimando, Joseph
AU - Rutella, Sergio
AU - Borcherding, Nicholas
AU - Parbhoo, Sonali
AU - Mukhopadhyay, Rupkatha
AU - Knaus, Hanna A.
AU - Valent, Peter
AU - Hackl, Hubert
AU - Borrello, Ivan M.
AU - Blazar, Bruce R.
AU - Hatzi, Katerina
AU - Gojo, Ivana
AU - Luznik, Leo
N1 - Publisher Copyright:
© 2024 American Society of Hematology
PY - 2024/9/12
Y1 - 2024/9/12
N2 - The interplay between T-cell states of differentiation, dysfunction, and treatment response in acute myeloid leukemia (AML) remains unclear. Here, we leveraged a multimodal approach encompassing high-dimensional flow cytometry and single-cell transcriptomics and found that early memory CD8+ T cells are associated with therapy response and exhibit a bifurcation into 2 distinct terminal end states. One state is enriched for markers of activation, whereas the other expresses natural killer (NK)-like and senescence markers. The skewed clonal differentiation trajectory toward CD8+ senescence was also a hallmark indicative of therapy resistance. We validated these findings by generating an AML CD8+ single-cell atlas integrating our data and other independent data sets. Finally, our analysis revealed that an imbalance between CD8+ early memory and senescent-like cells is linked to AML treatment refractoriness and poor survival. Our study provides crucial insights into the dynamics of CD8+ T-cell differentiation and advances our understanding of CD8+ T-cell dysfunction in AML.
AB - The interplay between T-cell states of differentiation, dysfunction, and treatment response in acute myeloid leukemia (AML) remains unclear. Here, we leveraged a multimodal approach encompassing high-dimensional flow cytometry and single-cell transcriptomics and found that early memory CD8+ T cells are associated with therapy response and exhibit a bifurcation into 2 distinct terminal end states. One state is enriched for markers of activation, whereas the other expresses natural killer (NK)-like and senescence markers. The skewed clonal differentiation trajectory toward CD8+ senescence was also a hallmark indicative of therapy resistance. We validated these findings by generating an AML CD8+ single-cell atlas integrating our data and other independent data sets. Finally, our analysis revealed that an imbalance between CD8+ early memory and senescent-like cells is linked to AML treatment refractoriness and poor survival. Our study provides crucial insights into the dynamics of CD8+ T-cell differentiation and advances our understanding of CD8+ T-cell dysfunction in AML.
UR - http://www.scopus.com/inward/record.url?scp=85196249895&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85196249895&partnerID=8YFLogxK
U2 - 10.1182/blood.2023021680
DO - 10.1182/blood.2023021680
M3 - Article
C2 - 38776511
AN - SCOPUS:85196249895
SN - 0006-4971
VL - 144
SP - 1168
EP - 1182
JO - Blood
JF - Blood
IS - 11
ER -